On August 13, McKesson fell 3.09% in regular trading, trading at $875.935/share, with turnover of $745 million.

On the news front, the broader Healthcare Distributors sector faced significant selling pressure, primarily triggered by peer Cencora's disclosure of ongoing margin headwinds from its GLP-1 drug product portfolio. Cencora's CFO further revealed during an earnings call that a potential merger of its MWI Animal Health and Covetrus units could generate approximately $150 million in operating profit headwinds, intensifying concerns about profitability quality across the sector. Cencora declined over 6% on the day, with Cardinal Health also falling 2.5% and Accendra Health down 4.37%.

McKesson's own fundamentals remain solid, having reported fiscal Q1 adjusted EPS of $9.93 on August 6, beating the consensus estimate of $9.54 by 4.09%, while revenue of $105.38 billion also exceeded expectations. The company simultaneously raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00, above the prior FactSet estimate of $44.26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)